<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855788</url>
  </required_header>
  <id_info>
    <org_study_id>KY2016-206</org_study_id>
    <nct_id>NCT02855788</nct_id>
  </id_info>
  <brief_title>Metronomic Chemotherapy in Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of Metronomic Chemotherapy Using POLF Regimen in the Treatment of Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Integrative Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin,
      Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 80% of patients with advanced gastric cancer are diagnosed at an advanced stage with
      limited treatment options including systemic chemotherapy with or without radiation. Commonly
      used maximally tolerated dose (MTD) chemotherapy such as DCT, ECF, FOLFOX regimens induce
      responses in the range of 20 to 50% with median survival in the range of 10 to 12 months.
      Metronomic chemotherapy has been found to have more consistent anti-tumor effects through
      anti-angiogenic and immunomodulating effects. Preliminary clinical studies of weekly POLF
      have found very encouraging clinical activities and low overall toxicities in pancreatic
      cancer and gastric cancer. Here we conduct a formal clinical trial to determine the clinical
      efficacy and side effect profiles of this regimen in patients with advanced gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>3 months</time_frame>
    <description>based on Recist 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>based on NCI-CTC v.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>median</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>median</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Gastric Cancer</condition>
  <condition>Locally Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>POLF regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly</intervention_name>
    <description>metronomic chemotherapy</description>
    <arm_group_label>POLF regimen</arm_group_label>
    <other_name>Taxol, Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically confirmed gastric cancer AJCC stage III or IV

          2. measurable disease based on CT or endoscopy exam

          3. non-surgical candidates or patients who declined surgery

          4. non-radiation candidates or patients who declined radiation

          5. patients who are able to sign informed consent

          6. patients who are 2 weeks out and recovered from surgery

          7. patients who have completed radiation to relieve obstructive symptoms

          8. patient who previously received Oxaliplatin and 5-FU in other MTD regimens

          9. adequate marrow function: neutrophil &gt;1000/ul, Hgb &gt;10g/dl, Plt&gt;50,000

        Exclusion Criteria:

          1. allergic to any of the drugs involved

          2. concurrent malignancies

          3. severe co-morbidities of heart, lungs, kidneys and bone marrow

          4. severe psychological disorder

          5. severe malnutrition

          6. difficult to heal or unhealed wound

          7. ECOG performance status equal or over 3

          8. uncontrolled complications from the malignancy

          9. uncontrolled CNS metastasis

         10. peripheral neuropathy grade 3 or above

         11. pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nick N Chen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Integrative Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Zhang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhongguang Luo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick N Chen, M.D., Ph.D.</last_name>
    <phone>206-588-1722</phone>
    <email>nicknchenmd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Liu, M.D.</last_name>
    <phone>021-5288236</phone>
    <email>jieliu@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seattle Integrative Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nick N Chen, M.D., Ph.D.</last_name>
      <phone>206-588-1722</phone>
      <email>nicknchenmd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Deb Ellifritt, BS</last_name>
      <phone>207-588-1722</phone>
      <email>debe@siccwa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nick N Chen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongguang Luo, M.D.</last_name>
      <phone>021-5288237</phone>
      <email>luozg8@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Zhang, M.D.</last_name>
      <phone>021-5288237</phone>
      <email>archsteed@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jie Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick N Chen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Nick Chen</investigator_full_name>
    <investigator_title>Visiting Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>gastroesophageal cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

